Alpha Tau Medical Ltd. DRTS
Updated: 9 Aug 2026
No signal published yet
We already track Alpha Tau Medical and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Alpha Tau Medical Ltd.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alpha Tau Medical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In July 2026, Alpha Tau reported positive clinical trial results for its Alpha DaRT radiation therapy in combination with pembrolizumab for head and neck cancer, showing a 100% objective response rate in evaluable patients. The company also announced in July 2026 that it treated the first patient in its ADMIRE study for recurrent cutaneous squamous cell carcinoma.
What Firelda Watch includes for Alpha Tau Medical Ltd.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Alpha Tau Medical Ltd.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alpha Tau Medical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more